WaveMan
WaveMan · Company
PCVX · Vaxcyte, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

PCVX Vaxcyte (PCVX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001649094
Quote by TradingView
Congress · 1Form 144 · 9
Insider buyers, 180 days
0
Funds added, last quarter
180
13F, latest reported quarter
Conversions, 180 days
12
Codes C/M, not in net · $1.2M priced

What the filings say about PCVX

Insiders, 180 days
-$10.4M net sold
5 sellers · 10% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-07-16
Planned sales (Form 144), 90 days
$5.3M
9 notices

Vaxcyte insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Vaxcyte, Inc. insiders sold a net $10.4M of stock across 469 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Cowan Elvia
SVP, Finance & CAO
SELL
2026-10-07 SECtraded 2026-10-05
19,000
$1.6M
-7.1%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Apr 7, 2026.
  • The trade is 68.2% of the 27,860 shares held after it.
  • 1 other insider sold within 30 days.
  • 180 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Finance & CAO Cowan Elvia sold about $1.6M of PCVX under a 10b5-1 plan on Oct 5, 2026, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 180 funds added in the latest 13F quarter.
Wassil Jim
EVP, Chief Scientific Ofc, COO
SELL
2026-10-07 SECtraded 2026-10-05
18,000
$1.6M
-7.1%
Context
  • 91 earlier Form 4 trades (code P or S) here by this insider (91 sales), the last on Oct 1, 2026.
  • The trade is 12.4% of the 145,435 shares held after it.
  • 1 other insider sold within 30 days.
  • 180 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Scientific Ofc, COO Wassil Jim sold about $1.6M of PCVX under a 10b5-1 plan on Oct 5, 2026, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 180 funds added in the latest 13F quarter.
Wassil Jim
EVP, Chief Scientific Ofc, COO
SELL
2026-10-02 SECtraded 2026-10-01
2,155
$122.1K
-18.1%
Context
  • 89 earlier Form 4 trades (code P or S) here by this insider (89 sales), the last on Sep 9, 2026.
  • The trade is 1.5% of the 145,530 shares held after it.
  • 1 other insider sold within 30 days.
  • 180 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Scientific Ofc, COO Wassil Jim sold about $122.1K of PCVX under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 180 funds added in the latest 13F quarter.
Wassil Jim
EVP, Chief Scientific Ofc, COO
SELL
2026-10-02 SECtraded 2026-10-01
95
$5.4K
-18.1%
Context
  • 89 earlier Form 4 trades (code P or S) here by this insider (89 sales), the last on Sep 9, 2026.
  • The trade is 0.1% of the 145,435 shares held after it.
  • 1 other insider sold within 30 days.
  • 180 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Scientific Ofc, COO Wassil Jim sold about $5.4K of PCVX under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 180 funds added in the latest 13F quarter.
Wassil Jim
EVP, Chief Scientific Ofc, COO
SELL
2026-09-09 SEC
1,334
$79.4K
+2.6%
Context
  • 88 earlier Form 4 trades (code P or S) here by this insider (88 sales), the last on Sep 4, 2026.
  • The trade is 0.9% of the 145,435 shares held after it.
  • 1 other insider sold within 30 days.
  • 180 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Scientific Ofc, COO Wassil Jim sold about $79.4K of PCVX on Sep 9, 2026; 1 other insider sold within 30 days and 180 funds added in the latest 13F quarter.
469 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 464 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$10.4M over 180 days
-$5.3M over 90 days
below 84% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
180 funds bought in last quarter
more than 87% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
12.6% of the float short (float per yahoo 2026-10-26) · 11.4 days to cover · settled 2026-09-30
more than 76% of Pharma & Biotech
What changed in the last 30 days
Oct 7EVP, Chief Scientific Ofc, COO Wassil Jim sold $1.7M under a 10b5-1 plan (3 trades, Oct 1 to Oct 5)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 7SVP, Finance & CAO Cowan Elvia sold $1.6M under a 10b5-1 plan (Oct 5)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 5Officer Cowan Elvia filed to sell $1.6M by Oct 5 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 5Officer Wassil Jim filed to sell $1.6M by Oct 5 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 1Officer Wassil Jim filed to sell $127.6K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch PCVX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+42.2%12M
-5%+21%+47%+74%2025-102025-122026-022026-042026-062026-082026-10 2026-10-05 · Cowan Elvia sold $1.6M2026-10-05 · Wassil Jim sold $1.6M2026-06-18 · PICKERING GRANT sold $1.2M2026-08-05 · Dhaliwal Harpreet S. sold $935.1K2026-07-27 · PICKERING GRANT sold $654.1K2026-06-18 · GUGGENHIME ANDREW sold $530.0K2026-06-26 · PICKERING GRANT sold $505.0K2025-12-31 · Dhaliwal Harpreet S. sold $454.9K2026-07-06 · GUGGENHIME ANDREW sold $452.3K2026-08-03 · GUGGENHIME ANDREW sold $374.0K2026-06-26 · PICKERING GRANT sold $362.8K2026-06-26 · PICKERING GRANT sold $360.1K2025-12-23 · Cowan Elvia sold $322.0K2026-03-10 · Wassil Jim sold $293.9K2026-07-27 · PICKERING GRANT sold $246.9K2025-12-23 · Cowan Elvia sold $235.0K2026-04-07 · Cowan Elvia sold $180.0K2026-08-03 · GUGGENHIME ANDREW sold $164.9K2026-03-11 · Cowan Elvia sold $146.5K2026-03-10 · Wassil Jim sold $141.5K2026-05-01 · Wassil Jim sold $127.9K2026-10-01 · Wassil Jim sold $122.1K2026-07-06 · GUGGENHIME ANDREW sold $120.6K2026-07-01 · Wassil Jim sold $100.2K2026-06-01 · Wassil Jim sold $96.3K2026-09-01 · Wassil Jim sold $93.6K2026-09-04 · Wassil Jim sold $84.5K2026-03-17 · Cowan Elvia sold $82.4K2026-04-01 · Wassil Jim sold $82.1K2026-09-09 · Wassil Jim sold $79.4K2026-08-03 · Wassil Jim sold $75.1K2026-09-01 · Wassil Jim sold $56.3K2026-06-18 · PICKERING GRANT sold $52.5K2026-04-01 · Wassil Jim sold $49.4K2026-08-03 · Wassil Jim sold $46.1K2026-09-01 · Wassil Jim sold $43.8K2026-07-27 · PICKERING GRANT sold $42.0K2026-07-27 · PICKERING GRANT sold $34.5K2026-06-26 · PICKERING GRANT sold $33.3K2026-07-01 · Wassil Jim sold $26.2K2026-03-17 · Cowan Elvia sold $22.8K2026-07-27 · PICKERING GRANT sold $21.1K2026-10-05 · Cowan Elvia filed to sell $1.6M2026-10-05 · Wassil Jim filed to sell $1.6M2026-10-01 · Wassil Jim filed to sell $127.6K2026-09-09 · Wassil Jim filed to sell $80.0K2026-09-04 · Wassil Jim filed to sell $82.5K2026-09-01 · Wassil Jim filed to sell $209.6K2026-08-05 · Dhaliwal Harpreet S. filed to sell $935.0K2026-08-03 · GUGGENHIME ANDREW filed to sell $539.9K2026-08-03 · Wassil Jim filed to sell $121.5K2026-07-27 · PICKERING GRANT filed to sell $996.7K2026-07-06 · GUGGENHIME ANDREW filed to sell $577.6K2026-07-01 · Wassil Jim filed to sell $130.8K2026-06-26 · PICKERING GRANT filed to sell $1.3M2026-06-18 · GUGGENHIME ANDREW filed to sell $530.0K2026-06-18 · PICKERING GRANT filed to sell $1.3M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PCVX: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
20,852,907 sh
$1.2B
Jupiter Topco LLC
17,965,847 sh
$1.0B
BlackRock, Inc.
12,068,129 sh
$701.5M
RA CAPITAL MANAGEMENT, L.P.
11,474,599 sh
$667.0M
WELLINGTON MANAGEMENT GROUP LLP
7,001,565 sh
$407.0M

Congress trades in PCVX

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Gilbert Cisneros
Bought 2026-07-16 · disclosed 50 days later
$1,001 - $15,000
Gilbert Cisneros
Bought 2026-05-13 · disclosed 26 days later
$1,001 - $15,000
Gilbert Cisneros
Bought 2026-05-12 · disclosed 27 days later
$1,001 - $15,000
Gilbert Cisneros
Bought 2025-04-28 · disclosed 8 days later
$1,001 - $15,000
Gilbert Cisneros
Bought 2025-04-15 · disclosed 21 days later
$1,001 - $15,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PCVX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Cowan Elvia
Filed 2026-10-05
$1.6M
Wassil Jim
Filed 2026-10-05
$1.6M
Wassil Jim
Filed 2026-10-01
$127.6K
Wassil Jim
Filed 2026-09-09
$80.0K
Wassil Jim
Filed 2026-09-04
$82.5K

PCVX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Eventide Healthcare & Life Sciences Fund
$48.1M position · as of 2026-06-30
2.7%
Harbor Health Care ETF
$848.8K position · as of 2026-07-31
2.1%
Fidelity Advisor Biotechnology Fund
$43.3M position · as of 2026-07-31
2.0%
PGIM Jennison Health Sciences Fund
$24.6M position · as of 2026-05-29
1.8%
Fidelity Disruptive Medicine ETF
$723.2K position · as of 2026-05-31
1.8%
Janus Henderson Transformational Growth ETF
$469.0K position · as of 2026-07-31
1.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
9 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
1 active
3
Phase 2
1 active
3
Phase 3
2 active
2
Multi-phase
0 active
What changed recently
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridgi
2026-10-17 · Active Not Recruiting → Completed
Phase 3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Grant E. Pickering
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$14.5M
-$26.7M
$4.9M
+76%
+42%
2024
$39.6M
$42.7M
$13.8M
+213%
+7%
2023
$12.1M
$28.1M
$4.8M
+140%
+9%
2022
$13.7M
$29.7M
$5.3M
+83%
+5%
2021
$5.3M
$4.3M
$1.9M
-9%
+18%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $10.4M sold by insiders over 180 days, 180 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $5.3M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PCVX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$894.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-10.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-9.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-38.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-9.9%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$923.7M-$569.5M-$468.0M-$232.3M
Net income-$766.6K-$463.9K-$402.3K-$223.5K
EPS (diluted)n/an/an/an/a
Operating cash flow-$655.6M-$452.6M-$296.8M-$170.6M
Cash$174.0M$387.9M$397.5M$834.7M
SEC XBRL, fiscal years, as known on 2026-10-27

PCVX Stock Sonar score 4/7 axes

Find similar shapesCompare

PCVX ranks highest on profitability (71st percentile) and institutional and government (71st), and lowest on insider conviction (8th), among Pharma & Biotech peers.

Profitability
71
Inputs
  • Return on equity-10.2% · 77 pct, sector of 545
  • Return on assets-9.3% · 75 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-38.7% · 60 pct, sector of 576
Insider conviction
8
Inputs
  • Net Form 4 buying (codes P and S), 180d-$7.0M · 17 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
71
Inputs
  • Funds adding, latest quarter180 · 87 pct, sector of 698
  • Congress net buyers, 365d1 · 60 pct, sector of 49
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$565K · 65 pct, sector of 133
Risk and compliance
31
Inputs
  • Short interest, % of float+12.6% · 31 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

PCVX filings, in plain words

Are Vaxcyte insiders buying or selling PCVX?

In the 180 days to 2026-10-27, Vaxcyte insiders were net sellers, a net $10.4M across purchases and sales reported on Form 4, by 5 sellers.

Have members of Congress traded PCVX?

Yes. In the year to 2026-10-27, 1 House member disclosed buying PCVX and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-07-16.

Are there planned insider sales of PCVX?

Yes. 9 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $5.3M of stock; the latest, by Cowan Elvia, was filed 2026-10-05.

Read the full summary

In the 180 days to 2026-10-27, Vaxcyte insiders were net sellers of PCVX, a net $10.4M across purchases and sales reported on Form 4 by 5 sellers. 10% of the 42 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-27, 1 member of Congress disclosed buying PCVX and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-07-16. Insiders filed 9 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $5.3M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies